{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CRC-BRAF Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CRC-BRAF Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CRC-KRAS Mutation, Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CRC-KRAS Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CRC-KRAS Mutation, Not Done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"GE-KRAS Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"GE-KRAS Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"NSCLC-KRAS Mutation, Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"NSCLC-KRAS Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"NSCLC-KRAS Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian-BRCA1 Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian-BRCA1 Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian-BRCA2 Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian-BRCA2 Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"SCCHN-APC Mutation, Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"SCCHN-APC Mutation, Not Done/Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"SCCHN-HPV (HPV-31 Positive) Mutation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"SCCHN-HPV Mutation, Not Done/Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"The number of participants with colorectal cancer (CRC), gastroesophageal cancer (GE), non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer or squamous cell carcinoma of head and neck (SCCHN) who had marker/molecular diagnostics performed prior to study entry to determine the mutation status of cancer genes: APC, BRAF, BRCA1, BRCA2, HRAS and KRAS and the presence of Human Papillovirus (HPV) and Epstein Barr viruses (EBV). Mutation/virus status was defined as: positive (mutation/virus present), negative (mutation/virus not present), unknown (mutation/virus status unknown), or not done (mutation/virus status was not done).","groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"OG000","title":"LY2523355"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Tumor Marker Values as Relevant to Specific Tumor Types at Baseline","type":"SECONDARY","unitOfMeasure":"Participants"}